Early psychosis prevention with cannabidiol (CBD)
Treatments studied
Part of Mental health clinical trials.
This trial tests if cannabidiol (a non-psychoactive cannabis component) can prevent psychosis in people ages 12-35 at high risk. It compares CBD to a placebo to see if it reduces symptoms and delays or prevents a first psychotic episode.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 12 and 35 years old.
- You have early warning signs of psychosis (like mild or brief psychotic symptoms) as determined by a specialist interview.
- You are not currently taking any antipsychotic medication (or have only taken it briefly).
- You agree to use effective birth control during the study if you could become pregnant.
- You have no major neurological conditions (like epilepsy) or a history of severe head injury.
- You are not currently pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called MT1988 in people who show early warning signs of psychosis. Researchers want to see if it changes certain markers in the body related to mental health.
This trial tests whether mindfulness training can help young people at high risk for psychosis avoid developing a full psychotic disorder. If you are between 18 and 30 and have early signs of psychosis, this program might be a way to get support and learn skills to stay well.
This study uses brain scans and a medication called methylphenidate (Ritalin) to understand how the brain chemical dopamine works in people at early risk for psychosis. It may help researchers find better ways to predict and treat psychosis.
This study explores how young people who are at high risk for psychosis or have had a first episode experience mindfulness. It uses interviews to understand their personal experience, which could help improve future treatments.
This trial tests a telehealth (video/phone) version of cognitive behavioral therapy to help young people who are at risk for developing psychosis. It may help by teaching skills to reduce symptoms and improve coping, with support from a key family or close person.
This study tests if adding a CBD medication to your current antipsychotic can improve symptoms in people with schizophrenia or related disorders who started treatment recently but aren't fully better yet.
Hear when a new Clinical High Risk for Psychosis (CHR) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.